

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Shah, Mansi R

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Assistant Professor, Division of Blood Disorders

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	END DATE MM/YYYY	FIELD OF STUDY
New York University, New York, NY	BS	05/2010	Biology, Psychology
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ	MS	05/2014	Medicine

**A. Personal Statement**

I received my undergraduate degree from New York University following which I matriculated from Rutgers Robert Wood Johnson Medical School. I completed an Internal Medicine internship and residency at Thomas Jefferson University Hospital in Philadelphia and returned to New Jersey to complete a fellowship in Hematology and Medical Oncology at Rutgers Cancer Institute of New Jersey/Robert Wood Johnson Medical School. During my fellowship, I was elected to serve as a chief fellow and participated in the Botswana-Rutgers Global Oncology Fellowship, with which I remain actively engaged in longitudinal curriculum development.

Navigating a new diagnosis of cancer can be overwhelming and life-changing for patients and their families. As a hematologist-oncologist, it is my privilege to advocate for my patients by not only helping them understand their diagnosis and treatment options but also by providing support and guidance. Being part of an NCI-designated Comprehensive Cancer Center in New Jersey allows me to provide my patients with personalized, state-of-the-art care through access to novel therapies and clinical trials to achieve the best possible outcomes.

My practice focuses on blood cancers including plasma cell disorders, leukemias, and bone marrow disorders. I have honed my interests by successfully participating in clinical research and am the author and co-author of numerous publications, reviews, abstracts, and presentations. I am actively involved in the development and execution of clinical trials. As a member of the Hematologic Malignancies Program, I am committed to providing comprehensive care with a patient-centered approach in collaboration with an exceptional multidisciplinary team of healthcare providers.

1. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilan MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshov DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy

with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. *Ann Oncol.* 2021 Jun;32(6):787-800. PubMed Central PMCID: PMC7972830.

2. Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Malecek MK, Watkins MP, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Evens AM, Shah M, Ahmed S, Stephens DM, Allen P, Tees MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Bailey NA, Pagel JM, Ramchandren R. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. *Clin Lymphoma Myeloma Leuk.* 2022 Jul;22(7):e435-e442. PubMed PMID: 35093285.
3. Kouya F, Iqbal Z, Charen D, Shah M, Banik RK. Evaluation of anxiety-like behaviour in a rat model of acute postoperative pain. *Eur J Anaesthesiol.* 2015 Apr;32(4):242-7. PubMed PMID: 24739517.
4. Shah MR, Jan I, Johns J, Singh K, Kumar P, Belarmino N, Saggiomo KJ, Hayes C, Washington K, Toppmeyer DL, Haffty BG, Libutti SK, Evens AM. SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center. *Cancer.* 2021 Jun 1;127(11):1926-1932. PubMed Central PMCID: PMC8014051.

## **B. Positions, Scientific Appointments and Honors**

### **Positions and Scientific Appointments**

- 2022 - Core Faculty, Rutgers Global Health Institute, Rutgers Cancer Center of New Jersey, New Brunswick, NJ
- 2021 - Core Faculty, Hematology-Oncology Fellowship Program, Robert Wood Johnson Medical School, New Brunswick, NJ
- 2021 - Course Director, Medical Student Clinical Oncology Elective, Rutgers Cancer Center of New Jersey, New Brunswick, NJ
- 2020 - Assistant Professor of Medicine, Rutgers Cancer Institute of New Jersey, Division of Blood Disorders, New Brunswick, NJ
- 2020 - Hematology, American Board of Internal Medicine
- 2020 - Medical Oncology, American Board of Internal Medicine
- 2019 - 2020 Teaching-Internal Medicine, Princeton Medical Center, Penn Medicine
- 2017 - Internal Medicine, American Board of Internal Medicine
- 2017 - 2020 Fellowship-Hematology Oncology, Robert Wood Johnson Medical School, New Brunswick
- 2014 - 2017 Internship & Residency, Thomas Jefferson University Hospital, Internal Medicine

### **Honors**

- 2019 - 2020 Chief Fellow, Hematology-Oncology Fellowship Rutgers Robert Wood Johnson Medical School
- 2021 Woman's Leadership Seminar, Women Faculty in Medicine and Science Institute, AAMC, Virtual
- 2017 Medical Education Pathway, Thomas Jefferson University Hospital
- 2014 Distinction in Service to the Community, Rutgers Robert Wood Johnson Medical School
- 2010 Honors Scholar, New York University

## **C. Contribution to Science**

1. Rutgers Cancer Institute of New Jersey. The Overall Goals of the Clinical Investigations and Precision Therapeutics (CIPT) Program are to 1) translate outstanding science across the Cancer Center into early phase trials, 2) develop novel diagnostic, prevention, and therapeutic strategies; and 3) promote bidirectional translation from bench to bedside and back. These goals are supported by close collaborations with the Cancer Metabolism and Immunology (CMI), Genome Instability and Cancer Genetics (GICG), and Cancer Pharmacology (CP) Programs. Translation of population science is done in collaboration with the Cancer Prevention and Control (CPC) Program.

I serve as the PI on the following studies:

Phase I/Ib: A Dose Escalation and Expansion Study of Lemzoparlimab as Monotherapy and in Combination with Backbone Agents for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma.

Sponsor: AbbVie

Role: Site PI

Phase I/II: First in Human Study of REGN5458(Anti-BCMA x Anti CD-3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma.

Sponsor: Regeneron

Role: Site PI

Phase II: Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor TCell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma

Sponsor: Janssen.

Role: Site PI Mansi R Shah, MD 9/2022- 5

Phase II: Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release.

Sponsor: Janssen

Role: Site PI

Teclistamab US Expanded Access Treatment Protocol for Patients with Relapsed or Refractory Multiple Myeloma.

Sponsor; Janssen

Role: Site PI

Phase III: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant.

Sponsor: Janssen

Role: Site PI

Phase III: A Phase II randomized, double-blind study of maintenance therapy with CC-5013 vs. placebo following autologous stem cell transplantation for multiple myeloma.

Sponsor: CALGB/ECOG

Role: Site P

## 2. Referenced Original Articles in Journal:

- a. Shah MR, Gabel A, Beers S, Salaru G, Lin Y, Cooper DL. COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e321-e326. PubMed Central PMCID: PMC8580561.
- b. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilén MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu

- H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. *Ann Oncol*. 2021 Jun;32(6):787-800. PubMed Central PMCID: PMC7972830.
- c. Shah MR, Jan I, Johns J, Singh K, Kumar P, Belarmino N, Saggiomo KJ, Hayes C, Washington K, Toppmeyer DL, Haffty BG, Libutti SK, Evens AM. SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center. *Cancer*. 2021 Jun 1;127(11):1926-1932. PubMed Central PMCID: PMC8014051.
- d. Tan AR, Sarantopoulos J, Lee L, Reyderman L, He Y, Olivo M, Goel S. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function. *Cancer Chemother Pharmacol*. 2015 Nov;76(5):1051-61. PubMed Central PMCID: PMC4612322.

Complete List of Published Work in My Bibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/cheryl.riga.1/bibliography/public/>